Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study

Bahtiri, Elton; Islami, Hilmi; Hoxha, Rexhep; Gashi, Afrim; Thaçi, Kujtim; Karakulak, Çağla; Thaçi, Shpëtim; Bytyqi, Hasime Qorraj

doi:10.5152/tjg.2016.0284

Cited by 17 publications

(15 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case–control study, with a patient population similar to ours (Mg levels at hospital admission), found no association of PPI use and hypomagnesemia . A few recent studies, albeit smaller in scope, also indicate no apparent association of PPIs and hypomagnesemia . A rare prospective study found stable Mg levels after 12 months of PPI use .…”

Section: Discussionsupporting

confidence: 64%

“…A few recent studies, albeit smaller in scope, also indicate no apparent association of PPIs and hypomagnesemia . A rare prospective study found stable Mg levels after 12 months of PPI use . Our study appears to be the only study to address Mg levels in separate groups that include high‐dose and low‐dose PPIs, with and without varying doses of diuretics.…”

Section: Discussionmentioning

confidence: 49%

See 1 more Smart Citation

Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use

Chowdhry

Shah

Kemper

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 49%

Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use

Chowdhry

Shah

Kemper

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…The methodology of this open - labelled prospective study is described in greater detail elsewhere [ 18 ] [ 19 ]. Briefly, the study population consisted of subjects aged 18 to 65 years with a confirmed diagnosis of osteoarthritis of small joints of the hands and on chronic NSAIDs that indicated to initiate gastroprotective maintenance therapy with PPIs.…”

Section: Methodsmentioning

confidence: 99%

Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 Months

Qorraj-Bytyqi¹,

Hoxha²,

Sadiku³

et al. 2018

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Proton pump inhibitors (PPIs) represent the most widely prescribed antisecretory agents, but their prolonged use, may influence iron and vitamin B12 status, which could have important implications for clinical practice.AIM:We undertook this study aiming to investigate the association between PPIs use for 12 months and potential changes in iron and vitamin B12 status, as well as whether this potential association varies among four specific PPI drugs used in the study.METHODS:A total of 250 adult subjects were recruited into this study, of which 200 subjects were PPIs users while 50 subjects belonged to the control group. Serum iron, ferritin, vitamin B12, and homocysteine (Hcy) levels were measured before the start of the study and after 12 months. Mann - Whitney U test and Kruskal - Wallis test was used to compare the baseline characteristics of the study groups, while Wilcoxon test was used to analyse post - pre differences.RESULTS:Statistical analysis showed significant changes within PPIs group and specific PPIs subgroups between the two-time points in serum ferritin and vitamin B12 levels, respectively, while no significant changes in serum iron and homocysteine levels were shown. However, subsequent diagnosis of hypoferremia and hypovitaminosis B12 in the whole study sample at 12 months was established in only 3.8% and 2.9% of the subjects, respectively.CONCLUSION:PPIs use for 12 months did not result in clinically significant iron and/or vitamin B12 deficiency; thus, these findings argue routine screening under normal circumstances, although monitoring in elderly and malnourished may be of precious value.

show abstract

“…Furthermore, in patients with achlorhydria, taking calcium with acidic meals can completely reverse the malabsorption of water-insoluble calcium. A recent prospective comparative study by Bahitri et al 48 .651, P = 0.008). Changes in serum levels of total calcium were accompanied by a statistically significant increase in serum PTH levels in patients treated with omeprazole, esomeprazole, and pantoprazole (z = ˗2.054, P = 0.040; z = 2.870, P = 0.004; z = ˗2.332, P = 0.020, respectively).…”

Section: Short-term Effectsmentioning

confidence: 94%

“…Furthermore, in patients with achlorhydria, taking calcium with acidic meals can completely reverse the malabsorption of water‐insoluble calcium. A recent prospective comparative study by Bahitri et al followed 250 patients for 12 months while on PPI therapy. The serum total calcium, and parathyroid hormone (PTH) levels were measured before and at 12 months after the initiation of PPIs.…”

Section: Adverse Effects Of Proton Pump Inhibitorsmentioning

confidence: 99%

Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome

2018

View full text Add to dashboard Cite

In recent years, proton pump inhibitors (PPIs) have been criticized for their various adverse interactions and side effects, creating a dilemma among practitioners regarding their use. Our goal is to review the proper use and possible side effects that might be caused by or associated with PPI use. Conclusions were drawn based on the evidence supporting or refuting short-term and long-term adverse events associated with PPI use. We also looked for the evidence regarding effects of PPIs on gut microbiota and their overall safety profile. Although there are significant discrepancies in the current literature regarding various adverse effects associated with PPI use, current data suggest that PPI use is not associated with an increased risk of bone fractures, community-acquired pneumonia, cardiovascular events, hypocalcemia, and gastric malignancies. A mild increased risk of vitamin B deficiency and chronic kidney disease, and a moderate increase in the risk of rebound hypersecretion, small intestinal bacterial overgrowth, and enteric infections, including Clostridium difficile, has been noted with PPI therapy. PPI's link with dementia and spontaneous bacterial peritonitis is not clear and requires further investigation. When used appropriately, PPIs are safe medications and are associated with minimal side effects. A clear indication and potential short-term and long-term side effects should be considered before starting PPI therapy.

show abstract

Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study

Cited by 17 publications

References 11 publications

Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use

Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use

Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 Months

Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome

Contact Info

Product

Resources

About